
Investments
96Portfolio Exits
45Partners & Customers
10About Celgene
Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. On November 21, 2019, Celgene was acquired by Bristol-Myers Squibb.

Want to inform investors similar to Celgene about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Celgene
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Celgene in 3 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Research containing Celgene
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Celgene in 2 CB Insights research briefs, most recently on Jun 2, 2022.
Latest Celgene News
Jan 25, 2023
Udaipur, INDIA 20 Maxwell House, Singapore, Jan. 25, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global gene therapy market is expected to clock US$ 4.64 billion by 2030 and to grow at a CAGR of 8.1% during the forecast period. Gene therapy focuses on cell reprogramming to provide a novel remedy/treatment method for a disease by replacing the damaged gene. This sort of treatment shows promising outcomes for a variety of diseases or disorders, including heart disease, hemophilia/acquired hemophilia, cancer, and many more. Gene therapy has several uses, the most important of which is the development of vaccines for various infectious or chronic illnesses. This exclusive information is published by Growth Plus Reports in its report titled “Gene Therapy Market – Global Outlook & Forecast 2022-2030” Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/gene-therapy-market/8079 Market Drivers The market's expansion can be attributed to the rising prevalence of chronic diseases such as cancer, central nervous system disease, metabolic disorders, cardiovascular disease, and so on. Additionally, the growing R&D activity has resulted in the continuously increasing introduction of innovative products/therapies and the enhancement of the product pipeline. Furthermore, rising financings such as IPOs (initial public offerings), venture capital financing, follow-on financing, and expanding partnerships and acquisitions significantly influence market growth. For instance, in 2022, Bayer AG and Mammoth Biosciences Inc. announced a strategic collaboration for the development of novel in-vivo gene editing technology. Bayer's gene therapy platform is strengthened further and Mammoth's vision of unlocking the full potential of novel CRISPR systems is also being supported. Additionally, Mammoth is expected to receive an upfront payment of USD 40 million, with potential future payments of more than a billion USD upon successful achievement. The gene therapy market has been analyzed from four perspectives: vector type, delivery type, application, end-users, and region. Excerpts from ‘By Vector Type Segmentation’ The vector type in the global gene therapy market has been bifurcated into: Viral Non-Viral Non-viral vector has the largest revenue share in the market as this is a safer treatment approach with a cheap cost, making it accessible to those with limited financial resources. This segment also possesses a high gene capacity, a low immunogenic response, a high transfection efficiency, and the ability to be chemically adaptable. Furthermore, rising cancer and other targeted illness cases and increased funding in gene therapy also contribute to the growth of this segment, thereby propelling the gene therapy market. While viral vectors are the most effective in gene therapy, they offer limited applications as a result of the limitation of chemical flexibility, thus depicting a steady growth during the projected timeline. Excerpts from ‘By Region Segmentation’ Geographically, the global gene therapy market has been segmented into: North America
Celgene Investments
96 Investments
Celgene has made 96 investments. Their latest investment was in Cyteir Therapeutics as part of their Series B - II on October 10, 2019.

Celgene Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
10/15/2019 | Series B - II | Cyteir Therapeutics | $40.2M | No | 4 | |
9/11/2019 | Series B | Anokion | $40M | No | 9 | |
8/28/2019 | Partnership - II | Immatics Biotechnologies | $75M | Yes | 5 | |
8/20/2019 | Series B | |||||
6/18/2019 | Series B - II |
Date | 10/15/2019 | 9/11/2019 | 8/28/2019 | 8/20/2019 | 6/18/2019 |
---|---|---|---|---|---|
Round | Series B - II | Series B | Partnership - II | Series B | Series B - II |
Company | Cyteir Therapeutics | Anokion | Immatics Biotechnologies | ||
Amount | $40.2M | $40M | $75M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 4 | 9 | 5 |
Celgene Portfolio Exits
45 Portfolio Exits
Celgene has 45 portfolio exits. Their latest portfolio exit was Human Longevity on June 21, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/21/2022 | Acq - Pending | 1 | |||
10/1/2021 | IPO | Public | 3 | ||
9/21/2021 | Acquired | 2 | |||
Date | 6/21/2022 | 10/1/2021 | 9/21/2021 | ||
---|---|---|---|---|---|
Exit | Acq - Pending | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 | 3 | 2 |
Celgene Acquisitions
14 Acquisitions
Celgene acquired 14 companies. Their latest acquisition was Juno Therapeutics on March 06, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/6/2018 | Series B | $310M | Acq - P2P | 5 | ||
1/8/2018 | Debt | $112.5M | Acquired | 3 | ||
2/14/2017 | Series A | $105.5M | Acquired | 1 | ||
1/26/2017 | Series A | |||||
12/2/2016 | Other |
Date | 3/6/2018 | 1/8/2018 | 2/14/2017 | 1/26/2017 | 12/2/2016 |
---|---|---|---|---|---|
Investment Stage | Series B | Debt | Series A | Series A | Other |
Companies | |||||
Valuation | |||||
Total Funding | $310M | $112.5M | $105.5M | ||
Note | Acq - P2P | Acquired | Acquired | ||
Sources | 5 | 3 | 1 |
Celgene Partners & Customers
10 Partners and customers
Celgene has 10 strategic partners and customers. Celgene recently partnered with Theranos on September 9, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
9/30/2021 | Partner | United States | Former Celgene scientist says partnership with Theranos ended over poor test quality - MassDevice Former Celgene scientist says partnership with Theranos ended over poor test quality . | 1 | |
1/19/2021 | Partner | United States | Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies. The ongoing partnership with Bristol Myers Squibb will enable the Recombinant Antibody Network to continue to develop and apply the latest technologies for the discovery of new cell-surface targets and the selection of clinically promising antibodies , as well as to expand research collaboration with the disease biology communities at the three universities . | 1 | |
10/18/2020 | Partner | United States | In October 2016 , Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations . | 1 | |
3/25/2020 | Partner | ||||
1/10/2020 | Licensor |
Date | 9/30/2021 | 1/19/2021 | 10/18/2020 | 3/25/2020 | 1/10/2020 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Licensor |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | Former Celgene scientist says partnership with Theranos ended over poor test quality - MassDevice Former Celgene scientist says partnership with Theranos ended over poor test quality . | Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies. The ongoing partnership with Bristol Myers Squibb will enable the Recombinant Antibody Network to continue to develop and apply the latest technologies for the discovery of new cell-surface targets and the selection of clinically promising antibodies , as well as to expand research collaboration with the disease biology communities at the three universities . | In October 2016 , Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations . | ||
Sources | 1 | 1 | 1 |
Celgene Team
33 Team Members
Celgene has 33 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Sheila DeWitt | Founder | Current | |
Name | Sheila DeWitt | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Compare Celgene to Competitors
BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

FoodMarble has developed a personal digestive tracker. Based on validated clinical technology, this tiny breath test device and app can be used with the help of AI to help people work out what foods are most compatible with their unique digestive system.

Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.
HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.